Can-Fite Ceo Pnina Fishman
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
/By Ilan Shavit/
Can-Fite BioPharma Ltd. (TASE:CFBI; Bulletin Board: CANFY) has obtained a patent from the US Patent and Trademark Office for its CF602 drug, which was licensed from the Leiden University, for the improvement of sexual dysfunction.
Can-Fite said that the patent expands and strengthens its intellectual property, allowing it to develop the drug for this indication and enter a market which the company estimates at $3 billion.
According to the company, during the clinical studies conducted with other drugs of the company, patients suffering from sexual dysfunction reported that they returned to normal function following the treatment with the company drugs. These findings are correlated with the company’s platform technology, which is targeting the A3 adenosine receptor as a therapeutic target.
Adenosine, like NO, is a potent and short-lived vasorelaxant that functions via cAMP signaling to promote smooth muscle relaxation. Recent studies show that adenosine functions to relax the corpus cavernosum and promote penile erection.
The company has filed a patent application for the treatment of sexual dysfunction utilizing the company drugs, and is planning to develop its 3rd pipeline drug, CF602, for this indication. CF602 is a novel A3 adenosine receptor allosteric modulator enhancing the affinity of the natural ligand adenosine to its A3 adenosine receptor. The company’s scientific team believes that the unique characteristics of the company drugs including the CF602 drug make it an applicable drug to be developed for the treatment of sexual dysfunction.
About Can-Fite Biopharma Ltd.
Can-Fite Biopharma Ltd is an Israeli public company, the ordinary shares of which are traded on the Tel Aviv Stock Exchange (TASE: CFBI). American Depository Receipts of the company are traded on the over-the-counter market (OTC: CANFY). The company, which commenced business activity in 2000, was founded by Pnina Fishman, Ph.D., researcher in the Rabin Medical Center, and Ilan Cohn Ph.D., patent attorney and senior partner at Reinhold Cohn Patent Attorneys. Pnina Fishman serves as CEO of the company. The company was founded on the basis of Fishman’s scientific findings, and is focused on the development of small molecule orally bioavailable drugs, ligands to the A3 adenosine receptor. The latter mediates anti-inflammatory and anti-cancer e